Sanofi, Regeneron COPD Drug Shows Mixed Results, Shares Drop

PARIS, France — An experimental medicine for chronic obstructive pulmonary disease (COPD) from Sanofi and Regeneron Pharmaceuticals has shown mixed results in two studies, the companies reported on Friday. This news prompted a decline in the stock prices of both firms.

The drug, itepekimab, is seen as a potential breakthrough as the companies hope to replicate the success of Dupixent, their highly successful medication for various immune-mediated diseases. Dupixent received approval for a wide range of conditions and has generated substantial sales.

Following the announcement, Sanofi’s shares dropped approximately 5% in early trading. Meanwhile, in pre-market trading in the U.S., Regeneron’s stock fell by more than 10%.

The mixed study results cast doubt on the drug’s future prospects, despite the high expectations surrounding itepekimab. The companies have yet to provide further details regarding the results of the trials or the next steps for the drug.

As the biopharmaceutical industry continues to seek advancements in treating respiratory diseases, the performance of itepekimab will be closely monitored by investors and stakeholders alike.